Skip to main content
SpringerLink
Log in

Role of Cannabinoid Receptors in Anxiety Disorders

  • Chapter
Cannabinoids and the Brain

Cannabinoid agents modulate anxiety, although their effects vary and depend on regional endogenous tone, basal anxiety levels, environmental context, species differences, type of anxiety, prior exposure, and dose. Cannabinoid receptors are densely located in brain areas that are involved in the regulation of emotional states and induce neurochemical responses that are congruent with anxiolyt ic/anxiogenic effects. The effects on emotion mediated by cannabinoid compounds are believed to be due to a regulation of activity at the cannabinoid CB1 receptors although there is some limited evidence implicating the cannabinoid CB2 and a putative novel cannabinoid receptor (GPR55?) in some of the observed emotional responses. Effects on emotion are likely the result of a net effect of the summated neurochemical responses. Compounds that indirectly regulate activity at the cannabinoid receptors more consistently reduce anxiety both in preclinical and clinical models. Consequently, these compounds may be the focus of future pharmaceutical development of anxiolytic compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, Rammes G (2004) Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24:9953–9961.

    Article  CAS  PubMed  Google Scholar 

  • Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6:257–268.

    Article  CAS  PubMed  Google Scholar 

  • Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Delta9-tetrahydrocannabinol. Psychopharmacology 163:111–117.

    Article  CAS  PubMed  Google Scholar 

  • Biscaia M, Marin S, Fernandez B, Marco EM, Rubio M, Guaza C, Ambrosio E, Viveros MP (2003) Chronic treatment with CP 55, 940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology 170:301–308.

    Article  CAS  PubMed  Google Scholar 

  • Braida D, Limonta V, Malabarba L, Zani A, Sala M (2007) 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555:156–163.

    Article  CAS  PubMed  Google Scholar 

  • Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005) Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516–524.

    Article  CAS  PubMed  Google Scholar 

  • Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G (2004) Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417–426.

    Article  CAS  PubMed  Google Scholar 

  • Degroot A, Nomikos GG (2004) Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test. Eur J Neurosci 20:1059–1064.

    Article  PubMed  Google Scholar 

  • Degroot A, Nomikos GG (2005) Fluoxetine disrupts the integration of anxiety and aversive memories. Neuropsychopharmacology 30:391–400.

    Article  CAS  PubMed  Google Scholar 

  • Degroot A, Nomikos GG (2007) In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol 7:62–68.

    Article  CAS  PubMed  Google Scholar 

  • Degroot A, Treit D (2002) Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res 949:60–70.

    Article  CAS  PubMed  Google Scholar 

  • Degroot A, Köfalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, Cunha RA, Nomikos GG (2006) CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 70:1236–1245.

    Article  CAS  PubMed  Google Scholar 

  • Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ (2000) The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacology 152:55–66.

    Article  CAS  PubMed  Google Scholar 

  • Gaetani S, Cuomo V, Piomelli D (2003) Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9:474–478.

    Article  CAS  PubMed  Google Scholar 

  • Genn RF, Tucci S, Marco EM, Viveros MP, File SE (2004) Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55, 940 in the social interaction test. Pharmacol Biochem Behav 77:567–573.

    Article  CAS  PubMed  Google Scholar 

  • Giuliani D, Ferrari F, Ottani A (2000) The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41:45–51.

    Article  PubMed  Google Scholar 

  • Gregg JM, Small EW, Moore R, Raft D, Toomey TC (1976) Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg 34:301–313.

    CAS  PubMed  Google Scholar 

  • Griebel G, Stemmelin J, Scatton B (2005) Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57:261–267.

    Article  CAS  PubMed  Google Scholar 

  • Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559.

    Article  CAS  PubMed  Google Scholar 

  • Guimaraes FS, de Aguiar JC, Mechoulam R, Breuer A (1994) Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol 25:161–164.

    CAS  PubMed  Google Scholar 

  • Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385.

    Article  CAS  PubMed  Google Scholar 

  • Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395–1398.

    Article  CAS  PubMed  Google Scholar 

  • Haller J, Varga B, Ledent C, Freund TF (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299–304.

    Article  CAS  PubMed  Google Scholar 

  • Haller J, Soproni K, Varga B, Nemeth B, Mikics E, Freund TF, Matyas F, Hajos N (2006) Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic/glutamatergic synaptic transmission. Sixteenth Annual Symposium on the Cannabinoids, ICRS, Tihany, Hungary.

    Google Scholar 

  • Hill MN, Gorzalka BB (2004) Enhancement of anxiety-like responsiveness to the cannabinoid CB1 receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499:291–295.

    Article  CAS  PubMed  Google Scholar 

  • Hill MN, Gorzalka BB (2006) Increased sensitivity to restraint stress and novelty-induced emotionality following long-term, high dose cannabinoid exposure. Psychoneuroendocrinology 31:526–536.

    Article  CAS  PubMed  Google Scholar 

  • Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53–79.

    Article  CAS  PubMed  Google Scholar 

  • Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115:3104–3116.

    Article  CAS  PubMed  Google Scholar 

  • Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68:1196–1202.

    Article  CAS  PubMed  Google Scholar 

  • Kataoka Y, Shibata K, Miyazaki A, Inoue Y, Tominaga K, Koizumi S, Ueki S, Niwa M (1991) Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology 30:475–480.

    Article  CAS  PubMed  Google Scholar 

  • Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25:10537–10545.

    Article  CAS  PubMed  Google Scholar 

  • MacLean KI, Littleton JM (1977) Environmental stress as a factor in the response of rat brain catecholamine metabolism to delta8-tetrahydrocannabinol. Eur J Pharmacol 41:171–182.

    Article  CAS  PubMed  Google Scholar 

  • Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, Wu D, Waku K, Sugiura T, Kano M (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 25:6826–6835.

    Article  CAS  PubMed  Google Scholar 

  • Manzanares J, Corchero J, Fuentes JA (1999) Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta9-tetrahydrocannabinol in rats. Brain Res 839:173–179.

    Article  CAS  PubMed  Google Scholar 

  • Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, File SE, Viveros MP (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55, 940 in male rats. Behav Pharmacol 15:21–27.

    Article  CAS  PubMed  Google Scholar 

  • Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C, Schmidhammer H, Viveros MP (2003) Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55, 940 in male rats. Pharmacol Biochem Behav 74:649–656.

    Article  CAS  PubMed  Google Scholar 

  • Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534.

    Article  CAS  PubMed  Google Scholar 

  • Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379–387.

    Article  CAS  Google Scholar 

  • Meneses A, Hong E (1993) Modification of the anxiolytic effects of 5-HT1A agonists by shock intensity. Pharmacol Biochem Behav 46:569–573.

    Article  CAS  PubMed  Google Scholar 

  • Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244.

    Article  CAS  PubMed  Google Scholar 

  • Moreira FA, Aguiar DC, Guimaraes FS (2006) Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 30:1466–1471.

    Article  CAS  PubMed  Google Scholar 

  • Musty R (1984) Possible anxiolytic effects of cannabidiol. In: Agurell S, Dewey WL, Willette RE (eds.), The Cannabinoids: Chemical, Pharmacological and Therapeutic Aspects. New York: Academic Press, pp. 795–813.

    Google Scholar 

  • Musty R, Conti LH, Mechoulam R (1984) Anxiolytic properties of cannabidiol. In: Harvey DJ (ed.), Marihuana 84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press, pp. 713–719.

    Google Scholar 

  • Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F (2005) Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 29:782–789.

    CAS  PubMed  Google Scholar 

  • Naliboff BD, Rickles WH, Cohen MJ, Naimark RS (1976) Interactions of marijuana and induced stress: forearm blood flow, heart rate, and skin conductance. Psychophysiology 13:517–522.

    Article  CAS  PubMed  Google Scholar 

  • Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491–496.

    Article  CAS  PubMed  Google Scholar 

  • Ng LK, Lamprecht F, Williams RB, Kopin IJ (1973) Delta9-tetrahydrocannabinol and ethanol: differential effects on sympathetic activity in differing environmental setting. Science 180:1368–1369.

    Article  CAS  PubMed  Google Scholar 

  • Onaivi ES (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54:231–246.

    Article  CAS  PubMed  Google Scholar 

  • Onaivi ES, Green MR, Martin BR (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002–1009.

    CAS  PubMed  Google Scholar 

  • Pamplona FA, Prediger RD, Pandolfo P, Takahashi RN (2006) The cannabinoid receptor agonist WIN 55, 212–2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology 188:641–649.

    Article  CAS  PubMed  Google Scholar 

  • Patel S, Hillard CJ (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304–311.

    Article  CAS  PubMed  Google Scholar 

  • Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004) Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431–5438.

    Article  CAS  PubMed  Google Scholar 

  • Patel S, Cravatt BF, Hillard CJ (2005) Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30:497–507.

    Article  CAS  PubMed  Google Scholar 

  • Pertwee RG (1997) Pharmacological of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180.

    Article  CAS  PubMed  Google Scholar 

  • Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51.

    Article  CAS  PubMed  Google Scholar 

  • Petitet F, Donlan M, Michel A (2006) GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67:252–253.

    Article  CAS  PubMed  Google Scholar 

  • Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21–38.

    Article  CAS  PubMed  Google Scholar 

  • Rakhshan F, Day TA, Blakely RD, Barker EL (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292:960–967.

    CAS  PubMed  Google Scholar 

  • Resstel LB, Joca SR, Moreira FA, Correa FM, Guimaraes FS (2006) Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 172:294–298.

    Article  PubMed  Google Scholar 

  • Rimonabant. New Drug Evaluation. Regional Drug & Therapeutic Centre (November 2006): No 78. Available at http://www.nyrdtc.nhs.uk/docs/nde/NDE_78_Rimonabant.pdf.

  • Rodgers RJ, Haller J, Halasz J, Mikics E (2003) ‘One-trial sensitization’ to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 17:1279–1286.

    Article  CAS  PubMed  Google Scholar 

  • Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16:405–413.

    Article  CAS  PubMed  Google Scholar 

  • Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M (1996) Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21, 38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276:56–64.

    CAS  PubMed  Google Scholar 

  • Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V, Guidali C, Realini N, Parolaro D (2007) Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32:2036–2045.

    Article  CAS  PubMed  Google Scholar 

  • Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043.

    Article  CAS  PubMed  Google Scholar 

  • Rutkowska M, Jamontt J, Gliniak H (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 58:200–206.

    CAS  PubMed  Google Scholar 

  • Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212–2. Behav Pharmacol 16:447–454.

    Article  CAS  PubMed  Google Scholar 

  • Takahashi RN, Pamplona FA, Fernandes MS (2005) The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 380:270–275.

    Article  CAS  PubMed  Google Scholar 

  • Tzavara ET, Wade M, Nomikos GG (2003) Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23:9374–9384.

    CAS  PubMed  Google Scholar 

  • Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966–973.

    Article  CAS  PubMed  Google Scholar 

  • Viveros MP, Marco EM, File SE (2005) Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331–342.

    Article  CAS  PubMed  Google Scholar 

  • Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H (1996) Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 19:1109–1111.

    CAS  PubMed  Google Scholar 

  • Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81–85.

    PubMed  Google Scholar 

  • Witkin JM, Tzavara ET, Nomikos GG (2005) A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16:315–331.

    Article  CAS  PubMed  Google Scholar 

  • Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76:245–250.

    Article  CAS  PubMed  Google Scholar 

  • Zuardi AW, Cosme RA, Graeff FG, Guimareas FS (1993a) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7:82–88.

    CAS  Google Scholar 

  • Zuardi AW, Guimaraes FS, Moreira AC (1993b) Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Braz J Med Biol Res 26:213–217.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astellas Pharma Europe B.V., Elisabethhof 1, 2350 AC Leiderdorp, The Netherlands

    Aldemar Degroot

Authors
  1. Aldemar Degroot
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Neurosciences of Coimbra, University of Coimbra, Coimbra, 3000-045, Portugal

    Attila Köfalvi (Faculty of Medicine) (Faculty of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Degroot, A. (2008). Role of Cannabinoid Receptors in Anxiety Disorders. In: Köfalvi, A. (eds) Cannabinoids and the Brain. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-74349-3_24

Download citation

Publish with us

Policies and ethics

Search

Navigation